ML281
CAS No. 1404437-62-2
ML281 ( ML-281 | ML-281 | ML281 )
产品货号. M17278 CAS No. 1404437-62-2
ML281 是一种有效的选择性 STK33 抑制剂,IC50 为 14 nM。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ¥645 | 有现货 |
|
| 10MG | ¥943 | 有现货 |
|
| 25MG | ¥1693 | 有现货 |
|
| 50MG | ¥2716 | 有现货 |
|
| 100MG | ¥3717 | 有现货 |
|
| 200MG | ¥5292 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
| 1 mL x 10 mM in DMSO | ¥550 | 有现货 |
|
生物学信息
-
产品名称ML281
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述ML281 是一种有效的选择性 STK33 抑制剂,IC50 为 14 nM。
-
产品描述ML-281 is a potent ans selective STK33 inhibitor (IC50 = 14 nM). ML281 showed low nanomolar inhibition of purified recombinant STK33 and a distinct selectivity profile as compared to other STK33 inhibitors. ML281 is a valuable addition to small-molecule probes of STK33. v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most mutated oncogene, and KRAS mutations have been found in up to 20% of all human tumors. STK33 was selectively toxic to KRAS-dependent cancer cell lines, suggesting that small-molecule inhibitors of STK33 might selectively target KRAS-dependent cancers.
-
体外实验Cell Viability Assay Cell Line:NCI-H446 cells Concentration:10 μM Incubation Time:72 hours Result:Suppressed cell viability of NCI-H446 cells.
-
体内实验——
-
同义词ML-281 | ML-281 | ML281
-
通路Others
-
靶点Other Targets
-
受体STK33
-
研究领域Cancer
-
适应症——
化学信息
-
CAS Number1404437-62-2
-
分子量389.47
-
分子式C22H19N3O2S
-
纯度>98% (HPLC)
-
溶解度DMSO : ≥ 30 mg/mL. 77.03 mM; H2O : < 0.1 mg/mL
-
SMILESO=C(c1cccs1)Nc1ccc(C(C)C)cc1c1nc2c(cccc2)[nH]c1=O
-
化学全称N-[2-(3,4-Dihydro-3-oxo-2-quinoxalinyl)-4-(1-methylethyl)phenyl]-2-thiophenecarboxamide
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
-
Quercetin 3,4-dimeth...
Quercetin 3,4'-dimethyl ether shows anti-lipid peroxidation activity (IC 50 values of 0.3 uM), it also shows anti-inflammatory activity.
-
[Cys0]-GTP-Binding P...
[Cys0]-GTP-Binding Protein Gsa (28-42); GTP-Binding Protein Fragment, Gs alpha
-
ELA-32 (human)
Potent, high affinity apelin receptor agonist (IC50 = 0.27 nM; Kd = 0.51 nM). Exhibits no binding GPR15 and GPR25. Activates the PI3K/AKT pathway and promotes self-renewal of hESCs via cell-cycle progression and protein translation. Also potentiates the TGFβ pathway, priming hESCs toward the endoderm lineage. Stimulates angiogenesis in HUVEC cells. Relaxes mouse aortic vessels. Functions as an anorexigenic hormone through activation of the AVP and CRH neurons in the PVN.
021-51111890
购物车()
sales@molnova.cn

